Targeting DNA repair and the cell cycle in glioblastoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Neuro-Oncology

• Publication date

  2012-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s11060-011-0765-4PMID 22113697
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas

  2011cited by this paper
• Molecular targeting of glioblastoma: Drug discovery and therapies.

  2011cited by this paper
• WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

  2011cited by this paper
• N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.

  2011cited by this paper
• COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

  2011cited by this paper
• Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation Membranrezeptorsignale und Kontrolle der DNA-Reparatur nach ionisierender Strahlung

  2010cited by this paper
• Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy

  2010cited by this paper
• Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization.

  2010cited by this paper
• Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130

  2010cited by this paper
• PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

  2010cited by this paper
• Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.

  2010cited by this paper
• Control of the G2/M checkpoints after exposure to low doses of ionising radiation: implications for hyper-radiosensitivity.

  2010cited by this paper
• In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.

  2010cited by this paper
• New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

  2010cited by this paper
• DNA repair targeting and radiotherapy: a focus on the therapeutic ratio.

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

  2010cited by this paper
• Enhancing radiotherapy through a greater understanding of homologous recombination.

  2010cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

  2009cited by this paper
• Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

  2009cited by this paper
• Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

  2009cited by this paper
• In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016

  2009cited by this paper
• Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

  2009cited by this paper
• Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

  2009cited by this paper
• Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.

  2009cited by this paper
• EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.

  2009cited by this paper
• Coordination of DNA Mismatch Repair and Base Excision Repair Processing of Chemotherapy and Radiation Damage for Targeting Resistant Cancers

  2009cited by this paper
• Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma

  2009cited by this paper
• Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

  2009cited by this paper
• Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells

  2009cited by this paper
• Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

  2009cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

  2008cited by this paper
• Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.

  2008cited by this paper
• Disassembly of MDC1 Foci Is Controlled by Ubiquitin-Proteasome-dependent Degradation*

  2008cited by this paper
• Targeting base excision repair for chemosensitization.

  2008cited by this paper
• Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance.

  2008cited by this paper
• Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability

  2008cited by this paper
• CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo

  2007cited by this paper
• Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors.

  2007cited by this paper
• UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.

  2007cited by this paper
• Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation*

  2007cited by this paper
• WHO classification of tumours of the central nervous system

  2007cited by this paper
• Triazene compounds: mechanism of action and related DNA repair systems.

  2007cited by this paper
• Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells.

  2007cited by this paper
• First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers

  2007cited by this paper
• The 2007 WHO Classification of Tumours of the Central Nervous System

  2007cited by this paper
• Proteasome function is required for DNA damage response and fanconi anemia pathway activation.

  2007cited by this paper
• ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage

  2007cited by this paper
• Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology

  2007cited by this paper
• The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

  2007cited by this paper
• Essential role for nuclear PTEN in maintaining chromosomal integrity.

  2007cited by this paper
• The DNA damage response: ten years after.

  2007cited by this paper
• Structure-Based Design of (5-Arylamino-2H-pyrazol-3-yl)-biphenyl-2‘,4‘-diols as Novel and Potent Human CHK1 Inhibitors

  2007cited by this paper
• STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.

  2006cited by this paper
• Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

  2006cited by this paper
• DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes.

  2006cited by this paper
• Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

  2006cited by this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways

  2006cited by this paper
• A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

  2006cited by this paper
• Poly(ADP-ribose): novel functions for an old molecule

  2006cited by this paper
• Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

  2006cited by this paper
• Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

  2006cited by this paper
• Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis

  2006cited by this paper
• The multifaceted mismatch-repair system

  2006cited by this paper
• Parp‐1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells

  2006cited by this paper
• γ-H2AX in Cancer Cells: A Potential Biomarker for Cancer Diagnostics, Prediction and Recurrence

  2006cited by this paper
• Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

  2006cited by this paper
• Emerging cancer therapeutic opportunities target DNA-repair systems.

  2006cited by this paper
• Targeted Modulation of MGMT: Clinical Implications

  2006cited by this paper
• The Biology of Cancer

  2006cited by this paper
• The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial

  2005cited by this paper
• Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

  2005cited by this paper
• New checkpoint blockers begin human trials.

  2005cited by this paper
• The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons*

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities.

  2005cited by this paper
• Cellular Response to DNA Damage

  2005cited by this paper
• Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft

  2005cited by this paper
• Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase.

  2004cited by this paper
• Targeting the checkpoint kinases: chemosensitization versus chemoprotection

  2004cited by this paper
• The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

  2004cited by this paper
• Knockdown of Chk1, Wee1 and Myt1 by RNA Interference Abrogates G2 Checkpoint and Induces Apoptosis

  2004cited by this paper
• Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks.

  2004cited by this paper
• MGMT: its role in cancer aetiology and cancer therapeutics

  2004cited by this paper
• Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells

  2004cited by this paper
• Cell-cycle checkpoints and cancer

  2004cited by this paper
• Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C

  2004cited by this paper
• Exploiting tumour hypoxia in cancer treatment

  2004cited by this paper
• Apurinic Endonuclease Activity in Adult Gliomas and Time to Tumor Progression after Alkylating Agent-Based Chemotherapy and after Radiotherapy

  2004cited by this paper
• Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

  2004cited by this paper
• Inhibition of Chk1 by CEP-3891 Accelerates Mitotic Nuclear Fragmentation in Response to Ionizing Radiation

  2004cited by this paper

• SUZ12 inhibition attenuates cell proliferation of glioblastoma via post-translational regulation of CDKN1B

  2023cites this paper
• Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas

  2023cites this paper
• Investigating the effects of arginine methylation inhibitors on microdissected brain tumour biopsies maintained in a miniaturised perfusion system.

  2023cites this paper
• Evaluation of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells Conditioning Medium (hWJ-MSCs-CM) or Scorpion Venom Breast Cancer Cell Line In Vitro

  2022cites this paper
• Recent developments in drug delivery strategies for targeting DNA damage response in glioblastoma.

  2021cites this paper
• Drug penetration through the blood–brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance

  2021cites this paper
• Investigating molecular targets of the DNA damage response in triple negative breast cancer

  2021cites this paper
• Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.

  2021cites this paper
• A Brain-Penetrating Hsp90 Inhibitor NXD30001 Inhibits Glioblastoma as a Monotherapy or in Combination With Radiation

  2020cites this paper
• Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms

  2020cites this paper
• A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase

  2019influential citation
• Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier

  2018cites this paper
• Effects of γ-radiation on cell growth, cell cycle and promoter methylation of 22 cell cycle genes in the 1321NI astrocytoma cell line.

  2017cites this paper
• Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells

  2017cites this paper
• Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma

  2017cites this paper
• Chitooligosaccharides promote radiosensitivity in colon cancer line SW480.

  2016cites this paper
• A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells

  2016cites this paper
• Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.

  2016cites this paper
• Comparative study of the chitooligosaccharides effect on the proliferation inhibition and radiosensitization of three types of human gastric cancer cell line.

  2016cites this paper
• Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance

  2015cites this paper
• The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment

  2015cites this paper
• The inhibition effect of expressions of miR-221 and miR-222 on glioma and corresponding mechanism.

  2014cites this paper
• Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors.

  2014cites this paper
• ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

  2014cites this paper
• Conditioned Media from Human Adipose Tissue-Derived Mesenchymal Stem Cells and Umbilical Cord-Derived Mesenchymal Stem Cells Efficiently Induced the Apoptosis and Differentiation in Human Glioma Cell Lines In Vitro

  2014cites this paper
• O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma

  2014cites this paper
• Transcriptome analysis of glioma cells for the dynamic response to γ-irradiation and dual regulation of apoptosis genes: a new insight into radiotherapy for glioblastomas

  2013cites this paper
• Chemo-sensitisation of HeLa cells to Etoposide by a Benzoxazine in the absence of DNA-PK inhibition

  2013cites this paper
• The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease.

  2013cites this paper
• Enhancing radiation therapy for patients with glioblastoma

  2013cites this paper
• [Occurrence and molecular pathology of low grade gliomas].

  2013cites this paper
• Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma

  2012cites this paper
• Molecular mechanisms of temozolomide resistance in glioblastoma multiforme

  2012cites this paper
• Risk and prognostic factors for malignant glioma

  2012cites this paper
• Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes*

  2011cites this paper